Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Trovagene Inc (NASDAQ:TROV)

Delayed Data
As of Nov 24
 +0.38 / +6.17%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Trovagene, Inc. is a development stage molecular diagnostic company that focuses on the development and commercialization of a proprietary urine-based molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. Its primary internal focus is to leverage its novel urine-based molecular diagnostic platform to facilitate improvements in field of oncology, while its external focus includes developing collaborations in the areas of infectious disease, transplant medicine and prenatal diagnostics. The company's proprietary urine-based molecular diagnostic tests are designed to detect specific nucleic acids in urine which are known as transrenal DNA and RNA. It's technology is applied in various testing, such as tumor detection and monitoring, prenatal genetic testing, infectious diseases, tissue transplantation, and forensic identification, as well as for patient selection in clinical trials. Trovagene was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.

Contact Information

TrovaGene, Inc.
11055 Flintkote Avenue
San Diego California 92121
P:(858) 952-7570
Investor Relations:



Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Antonius P. SchuhChief Executive Officer & Director
Stephen L. ZaniboniChief Financial Officer
Mark ErlanderChief Scientific Officer
Vlada MelnikovaVice President-Research & Development
Matthew L. PosardChief Commercial Officer & Executive VP